Category Archives: AFTNews

PRNews

PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for Its Proprietary DETOUR System for Percutaneous Bypass

Novel technology enables a new, minimally invasive treatment for patients suffering from extremely long peripheral artery blockages

LONDON, Aug. 31, 2017 /PRNewswire/ — Frost & Sullivan is pleased to recognize PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award. PQ Bypass’ DETOUR System is a minimally invasive technology that enables physicians to re-direct, or detour, blood flow around extremely long blockages in the upper leg arteries to restore blood flow to the lower leg and foot.

“PAD is a potentially fatal condition that affects more than 200 million people worldwide—3 to 12% of the global population. PQ Bypass’ proprietary DETOUR System is a promising, innovative approach for patients with extremely long lesions whose current treatment options are not ideal,” said Frost & Sullivan Best Practices Analyst, Norma Vela. “We anticipate rapid, widespread technology adoption once the DETOUR System launches commercially. The global market potential for treating this type of advanced peripheral arterial disease is significant, and PQ Bypass has first-mover status in the space.”

Extremely long blockages in the leg arteries, especially those that are greater than 20 centimeters, are challenging to treat. Historically, physicians have treated these blockages with open bypass surgery (fem-pop bypass), which has the benefit of durability, however, it is associated with an increased risk of complications, longer hospital stays, and prolonged rehabilitation. More recently, minimally-invasive technologies have emerged that go through blockages. These technologies work very well on shorter blockages; however, they have not been as effective on these longer blockages as open surgery.

The DETOUR System is designed to deliver the durability advantages of open bypass surgery with a minimally-invasive approach. During a DETOUR procedure, a pathway is created by crossing from the SFA into the femoral vein and back into the artery that allows DETOUR stent grafts to be placed in a continuous line. The new path through the stent grafts re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient.

“With an increased focus on value-based and patient-centered medicine, surgical advancements that minimize trauma to patients, reduce length of hospital stay and recovery times are critical global needs,” said Richard Ferrari, Chairman of the Board of PQ Bypass. “We designed the DETOUR System to be a transformative step forward in how physicians treat extremely long peripheral artery disease.”

In March 2017, PQ Bypass received CE Mark approval for the DETOUR System and is planning a pivotal investigational device exemption study to support premarket approval from the US Food and Drug Administration (FDA). The clinical results of the DETOUR I trial conducted in Europe were promising, demonstrating excellent safety and effectiveness with patency results of 84.7% at 6 months.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and develops newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices Awards acknowledge companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.

PQ Bypass is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, and Stryker and also have extensive experience developing medical devices for startups such as Evalve, Access Closure, Avinger, and DVI.

The underlying technology and technique used in the percutaneous PQ DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in PAD.

The PQ Bypass technology platform is not available for sale in the US. For more information, please visit www.pqbypass.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Fit Tech & Gadgets, PRNews

A Glimpse into the Future of Wearable Healthcare: Going Way Beyond Smartwatches and Fitness Trackers

OYSTER BAY, New York, Aug. 30, 2017 /PRNewswire/ — The healthcare wearables market accounts for US$6.8 billion of the current US$25 billion wearables market. ABI Research forecasts that Wearable Healthcare, including healthcare devices, sports, fitness, and wellness trackers will continue to dominate the wearables market and will exceed revenues of US$10 billion in 2022.

Healthcare wearables that monitor health conditions, physical performance, and brain activity will move beyond smartwatches and fitness trackers; they will shrink in size and change in form factor type. Unlike today’s bulky health related devices, ultra-thin and ultra-soft sensors with software analytics make next-generation wearables smarter and more useful. 

“As an ultimate form factor of wearables, flexible body-worn sensors are quite an innovation for wearable adoption in healthcare, fitness, and human-machine interface,” says Marina Lu, Senior Analyst at ABI Research. “These sensors can be integrated into a small patch and attached to human skin surface to track vital signs and other biometrics continuously and wirelessly. Some of the implementation examples include electronic tattoos and skin sweat sensors.”

The electronic tattoo developed by Rotex performs many of the typical functions of smart watches and fitness trackers. Not only does it monitor health conditions in real-time, it also provides a different means to control devices as an integral part of IoT. The low cost and disposability of the electronic tattoos further the use cases and value appeal of wearable technology, especially for customers who are price sensitive.

Replacing costly doctor visits and painful lab-based blood tests, non-invasive sweat sensors can measure a set of key biometrics from a single bead of sweat. A few companies are working to capture the sweat sensor market, such as Eccrine System, GraphWear Technologies and Kenzen.

These sensors require flexible components and startup Royole is leading the way. Royole’s plan for mass production of flexible displays and sensors will accelerate the technology adoption for wearables and facilitate more aesthetically-pleasing wearable designs, smaller form factors, and more immersive experiences.

“Health sensors are becoming increasingly commoditized, as they allow continuously physical monitoring with reduced manual intervention and at low cost,” concludes Lu. “While the miniaturized health sensors enable consumers to monitor health conditions by themselves and be aware of their own health care, they also extend to the enterprise market by delivering superior analytics for clinical and medical research. Once privacy and security concerns are addressed and standardization in health communication protocols are put into place, the next-gen of wearable healthcare will be ushered in.” 

These findings are from ABI Research’s Hot Tech Innovators: Wearables report. This report is part of the company’s Wearables, Usables & Expendables research service, which includes research, data, and analyst insights. 

About ABI Research

ABI Research stands at the forefront of technology market intelligence, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: 

Americas                                      

EMEA/APAC

Deborah Petrara                           

Denise Duffy

Tel: +1.516.624.2558                    

Tel: +44.203.326.0142

pr@abiresearch.com                      

duffy@abiresearch.com
PRNews

Merck Opens its First Customer Food Safety Studio

– New Food Safety Studio in Bellevue, Washington, serves as global center for innovation and collaboration

– Demonstration and training lab space extends product and process development to customers

DARMSTADT, Germany, Aug. 30, 2017 /PRNewswire/ — Merck, a leading science and technology company, has opened its first global Food Safety Studio in Bellevue, Washington for manufacturers of all types of food (beef, poultry, produce, etc.) to collaborate with Merck scientists on developing safety products for rapid detection of foodborne pathogens.

The new 5,300-square foot center gives customers access to a complete food safety workflow, from raw materials testing to finished-product safety testing, to help find, correct and prevent hazards within the food supply chain. The center allows customers to work with many manual or automated food safety products such as testing kits and hygiene swabs that are critical to maintaining safety throughout the manufacturing process.

“The opening of Merck’s Food Safety Studio demonstrates our commitment to ensuring the safety of the global food supply,” said Jean-Charles Wirth, Head of the Applied Solutions business unit, Life Science at Merck. “We are bringing teams together in a workspace designed to foster open innovation and collaboration with the goal of becoming the leader in food safety testing.”

According to the World Health Organization, an estimated 600 million people in the world — almost one-in-10 — fall ill after eating contaminated food, and 420,000 die every year.

Merck, which earlier this year acquired BioControl Systems, a global leader in food safety testing, helps customers protect the global food supply by providing a comprehensive portfolio of state-of-the-art testing technologies.

Customer visits are being scheduled for the new Food Safety Studio, which features a Food Safety Demonstration Center designed with a classroom setting and demonstration lab.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Merck Collaborates with Angiex to Speed Clinical Readiness of New Cancer Therapy

– Project is first for Merck’s Massachusetts BioReliance® End-to-End Solutions center

– Collaboration gives Angiex access to Merck’s process development tools and technologies

DARMSTADT, Germany, Aug. 29, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up’s ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody-drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.

The collaboration with Angiex is the first project to be undertaken at Merck’s new biodevelopment center in Massachusetts, USA. Merck will give Angiex access to end-to-end process development tools, education programs and training to support its success.

“Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer for companies like Angiex.”

Angiex CEO Dr. Paul Jaminet applauded Merck’s broad range of process development capabilities and services for customers at all stages of molecule development and commercialization. “Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate Merck’s expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors,” Jaminet said.

Merck’s BioReliance® End-to-End Solutions deliver products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance® End-to-End Solutions, Merck will inaugurate its new biodevelopment center in Burlington, Massachusetts in October 2017.

Merck’s BioReliance® End-to-End Solutions is part of the Process Solutions business area within the Life Science business of Merck.

About Angiex
Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex’s lead product is an antibody-drug conjugate therapy for cancer. Angiex is resident at LabCentral in Cambridge, Massachusetts.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Ganeden Brings Probiotic Exhibit and Expertise to Fi Asia

Global leader will discuss probiotic formulation trends, science updates and product launches

CLEVELAND, Aug. 29, 2017 /PRNewswire/ — As probiotic fortification continues to gain momentum around the world, probiotic leader Ganeden is expanding its presence at additional food and beverage events globally—including in Asia. This September, experts from the top probiotic ingredient supplier will be attending Food Ingredients Asia (Fi Asia) in Bangkok. Team members based locally and from the U.S. headquarters will be on site to discuss new probiotic research, offer insight into upcoming product launches and help manufacturers explore innovative probiotic formulations beyond traditional dairy applications.

Ganeden has become a driving force in the probiotic space internationally, helping hundreds of manufacturers use probiotic technology in their products in innovative ways—including many in Asia. As a global leader, the science-driven company is knowledgeable on probiotic trends around the world, including consumer demand, research advancements and innovative options for probiotic fortification beyond the dairy case. Experts can assist in probiotic ingredient selection, including providing details on strain specificity, study requirements and health benefits.

“There are tremendous growth opportunities for probiotic technologies in the Asian market, and Fi Asia gives us a chance to provide expertise on how health benefits can be added to products to drive consumer interest and purchases,” said Stephen Quinn, business and regulatory director for Asia at Ganeden. “We plan to meet with industry leaders and innovators to demonstrate how functional ingredients can benefit end-users and grow business. There is a strong tradition of probiotics in Asia, but nearly all of it is in the supplement and dairy categories, so having a chance to provide the same health benefits in other food and beverage applications is exciting for manufacturers and their customers.”

Ganeden is best known for GanedenBC30® (Bacillus coagulans GBI-30, 6086), its patented and shelf stable probiotic ingredient that remains viable through most manufacturing processes, shelf life and gastric transit—allowing it to be fortified into almost any food or beverage product. Years of ongoing studies confirm the strain’s safety, digestive and immune support, and protein utilization benefits. And because GanedenBC30 has been shown to survive 10X more effectively than yogurt cultures, it has become one of the top ingredient choices for probiotic benefits in both refrigerated and non-refrigerated products.

During the show, Ganeden will also introduce the newest addition to its ingredient portfolio—Staimune™. The new ingredient uses the inactivated cells of GanedenBC30, which have been shown to support immune health. Staimune’s ease of formulation opens up new opportunities in immune-focused, functional foods and beverages which involve processes too harsh for live probiotics.

To meet with probiotic experts at the Fi Asia show, contact Ganeden or visit booth #F34. For more information on the probiotic company, including its ingredient portfolio, research and international presence, visit GandedenProbiotics.com.

About Ganeden:

Ganeden® is at the forefront of probiotic research and product development with an extensive library of published studies and more than 135 patents for probiotic technologies in the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30®, its patented, FDA GRAS, highly stable probiotic ingredient. Through the fermentation process of GanedenBC30, Ganeden developed Bonicel®, the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. Ganeden’s newest ingredient, Staimune™ is a patented probiotic technology comprising of inactivated GanedenBC30 which has been shown to have immune benefits. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com. 

PRNews

Merck to Acquire Natrix Separations to Advance Next-Generation Processing Capabilities

— Boosts Merck’s single-use chromatography portfolio

— Accelerates Merck’s mAb and vaccine manufacturing offering

DARMSTADT, Germany, Aug. 28, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced that it has entered into an agreement to acquire Natrix Separations, an Ontario, Canada-based provider of hydrogel membrane products for single-use chromatography. The transaction is expected to close in Q3 of 2017. Financial details were not disclosed.


Merck signed an agreement to acquire Natrix Separations, a company known for its technology platform capable of delivering high productivity and impurity removal in a single-use format. This acquisition complements Merck’s efforts to drive next-generation bioprocessing, ultimately enabling faster, more efficient technology for customers. Pictured here is a magnified view of the Natrix HD Membrane pore structure, comprised of up to 95 percent functional monomer.

Natrix is known for its unique technology platform capable of delivering high productivity and impurity removal in a single-use format, an ideal fit with next-generation processing. This acquisition complements Merck’s efforts to drive next-generation bioprocessing, ultimately enabling faster, more efficient technology for its customers.

“The Natrix technology platform, and the development options and capabilities that this brings for single-use and rapid cycling chromatography, will allow us to accelerate our offering in mAb and vaccine manufacturing,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “This acquisition creates tremendous opportunity to drive growth and advancement in next-generation processing—an area of increasing importance to our customers.”

Next-generation processing is any technology, expendable or system that changes the existing monoclonal antibody manufacturing template through unit operation intensification, connection of unit operations, or fully continuous processing. Biomanufacturers are moving toward next-generation processing because of its many benefits, including increased plant productivity, facility flexibility, cost efficiencies and reduced risk. Next-generation processing is expected to triple in market size between 2020 and 2025.

Natrix markets both an anion exchange membrane and cation exchange membrane. Natrix is developing additional products to enable a fully single-use, full-scale biological purification process.

“Joining Merck gives us the opportunity to collaborate with some of the best minds in the industry, allowing us to further the great work done by our scientists,” says John Chickosky, CEO, Natrix Separations. “I am truly excited to become part of a larger effort and see the benefits of this combination in the advances we will make for our customers and the global scientific community.”

About Natrix Separations, Inc.
 Natrix Separations enables fast and flexible manufacturing of biopharmaceuticals through high-productivity disposable downstream processing products. The innovative Natrix HD Membranes overcome the limitations in efficiency, speed, and flexibility imposed by conventional capital-intensive approaches to chromatography. Natrix products feature well-established industry-standard chemistries, and are scalable from R&D to commercial manufacturing. Natrix is headquartered in Burlington, Ontario, Canada. For additional information, visit www.natrixseparations.com

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
 Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.
Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo – https://mma.prnewswire.com/media/548923/Merck_Acquires_Natrix_Separations.jpg

PRNews

Tekni-Plex begins production at new China manufacturing facility

$15 million investment supports Tekni-Plex’s continued commitment to global supply network

WAYNE, Pennsylvania, Aug. 28, 2017 /PRNewswire/ — Tekni-Plex, Inc.’s new state-of-the-art manufacturing facility in Suzhou, China, near Shanghai has begun production. The company will hold a grand opening celebration on September 19th.


Tekni-Plex, Inc.’s new state-of-the-art manufacturing facility in Suzhou, China, near Shanghai has begun production. The company will hold a grand opening celebration on September 19th. The facility is producing Natvar’s recently-announced silicone extrusion tubing and Colorite custom compounds for medical device applications. Production will also include Action Technology’s dip tubes for food/beverage, pharmaceutical, personal care, industrial and household pump products.

Earlier this year, Tekni-Plex announced a $15 million investment in the facility to support the growing needs of the Asia-Pacific pharmaceutical and medical device market.

The more than 140,000-square-foot (13,000-square-meter) facility has already started manufacturing products for Tekni-Plex’s Natvar, Colorite and Action Technology business units. The facility features three Class 100K cleanrooms to accommodate medical-grade tubing and components production plus one Class 10K cleanroom that will produce Natvar’s pharma-grade tubing.

The facility is producing Natvar’s recently-announced silicone extrusion tubing for catheters, feeding tubes, drug delivery and peristaltic pump applications. Production for microextrusion tubing that targets a wide variety of demanding neurovascular interventional therapies and surgical applications is expected to be onstream early next year. The facility will also manufacture Colorite custom compounds for medical device applications, and Action Technology’s dip tubes used in a wide variety of food/beverage, pharmaceutical, personal care, industrial and household pump applications.

Among those representing Tekni-Plex at the ribbon cutting will be Paul Young, chief executive officer, Russell Hubbard, vice president-international and general manager, Ian Kenny, global managing director, Colorite, and Bob Donohue, general manager of the company’s Natvar business unit.  Local officials are also expected to attend.

For further information about attending the event contact Coco Xu at Coco.Xu@tekni-plex.com.

About Tekni-Plex, Inc.
Celebrating its 50th anniversary in 2017, Tekni-Plex is a globally-integrated company focused on developing and manufacturing innovative packaging materials, medical compounds and precision-crafted medical tubing solutions for some of the most well-known names in the medical, pharmaceutical, personal care, household and industrial, and food and beverage industries. Tekni-Plex is headquartered in Wayne, Pennsylvania, and operates manufacturing sites across eight countries worldwide to meet the needs of its global customers.  For more information visit www.tekni-plex.com.

Logo – http://mma.prnewswire.com/media/177084/tekni_plex_logo.jpg

Source: Tekni-Plex, Inc.

PRNews

Why do hair loss prevention and treatment industries pay attention to P1P, a cell-regenerating substance developed in Korea?

-Its effectiveness in overcoming and preventing stress hair loss comes into light

ANYANG, South Korea, Aug. 24, 2017 /PRNewswire/ — P1P (Phytosphingosine 1 Phosphate), a cell-regenerating substance developed in Korea, which is thought to be effective in overcoming hair loss caused by stress, is now drawing attention from the domestic hair loss prevention and treatment industry.


Dr. Myung-Joon Choi of KAIST who released P1P

It was learned that ‘S1P(Sphingosine 1 Phosphate),’ a substance found minimally in the blood, helps to regenerate cells in the body and prevent aging, is effective in preventing necrocytosis due to stress. However, the idea did not lead to the development of products owing to expensive prices.

Under such circumstances, a team of doctors at KAIST continued to delve into the matter in search of its analogs, and succeeded in identifying P1P. By applying P1P to cosmetic and hair loss prevention products, ‘P1P’, a ‘phytosia’ and aesthetic skin care brand, was launched into the market, earning a patent associated with prevention and treatment of hair loss, and a composition for hair growth. From this connection, a skin and hair society in Europe announced the effect of P1P on the mechanism of hair growth.

Dr. Myung-Joon Choi of KAIST who released P1P said, “While studies are actively under way on the application of P1P worldwide, the projects have met a limitation, that is, it is prohibitively expensive, making it a project of low marketability. Under such circumstances, I am so glad that we managed to open the possibility of commercializing the substance since we have secured a technology of synthesizing the substance for mass production. We will continue to work steadily on the project to introduce better products.” 

The P1P substance developed by Korea’s phyto-associated industries are expected to find extensive applications in the domestic medical and bio-industry for stem cell culture technology and the treatment of degenerative neurological diseases.

Contacts:

PHYTOS Co., Ltd.
Myeongjun Choi
Mobile: +82)10-9369-5339
Office: +82)70-7404-6642
Email: myeongjun@p1p.kr

View original content with multimedia:http://www.prnewswire.com/news-releases/why-do-hair-loss-prevention-and-treatment-industries-pay-attention-to-p1p-a-cell-regenerating-substance-developed-in-korea-300509167.html

PRNews

Young Living Essential Oils Promotes Lauren Walker to Chief Supply Officer

-Walker Leads the Sourcing Pillar of Young Living’s Seed to Seal Program-

LEHI, Utah, Aug. 18, 2017 /PRNewswire/ — Young Living Essential Oils, the world leader in essential oils, today announced that it has promoted Lauren Walker to the role of Chief Supply Officer. In her time with Young Living, she and her team have further implemented rigorous sourcing standards while also streamlining manufacturing, warehousing and fulfillment operations.

“Lauren embraces Young Living’s passion for being stewards of the earth and has been a driving force in ensuring that the sourcing, manufacturing and shipping components of our business all operate under that mindset,” said Jared Turner, Young Living Chief Operating Officer. “Her experience and expertise in project management, manufacturing, and supply chain gained throughout her career has been a great addition to our strong executive team.”

Walker leads the sourcing pillar of Young Living’s Seed to Seal program (Sourcing, Science and Standards), that governs how we obtain our products — whether from our corporate-owned farms, partner farms, or Seed to Seal-certified supplier. The sourcing pillar is also a major part of how we verify, through internal and third-party tracking, that the superior essential oils and premium ingredients in our products such as foods, skin care, and supplements were produced and manufactured according to industry best practices and our own high standards.

“We have an obligation to provide our customers with the highest quality products and the best customer experience, and we do that by having effective processes in place,” said Walker. “I’m proud that our team has assessed the whole supply chain of an oil and refined or established processes that help us provide the best products and services to our customers.”                   

Throughout her three-decade career with high-profile international companies, Walker has established herself as a leader and an innovator in streamlining global systems. After completing her engineering degree, she worked for Xerox as an engineer, followed by 10 years with Procter & Gamble in supply chain, manufacturing/technical operations, and quality. She also worked for seven years with Johnson & Johnson as a plant manager and as Program Manager of their Oral Care franchise. Prior to joining Young Living in 2016, she was Vice President of Manufacturing at Amway, where she was responsible for manufacturing across all product lines: nutrition, home care, personal care, beauty care, durable goods, and paper products.

In addition to her extensive experience, Walker has been a keynote speaker for American Manufacturing Strategies Summit and Front End Innovations Conference, is a Lean Six Sigma Project Champion in Manufacturing, and is Green Belt Certified. She holds a degree in engineering from Union College in New York. Lauren currently serves on the Board of Directors for the Salt Lake Chamber.

About Young Living Essential Oils
Young Living Essential Oils, LC, is the world leader in essential oils, with a strict Seed to Seal® process that produces pure essential oil products for every individual, family, and lifestyle. This process ensures that all products are genuine, free of synthetic chemicals, and pure. This commitment stems from the company’s more than 20 years of stewardship toward the earth and its people. For more information, visit YoungLiving.com.

Media Contact:
For media inquiries, please contact prinquiries@youngliving.com.

Photo – https://mma.prnewswire.com/media/546503/Lauren_Walker_Young_Living_Essential_Oils.jpg
Logo – https://mma.prnewswire.com/media/323110/Young_Living_Essential_Oils_Logo.jpg

PRNews

OpenEye Announces Pfizer To Adopt Orion Cloud Platform For Computational Chemistry

SANTA FE, New Mexico, Aug. 17, 2017 /PRNewswire/ — OpenEye Scientific Software, Inc., an innovative developer of molecular modeling and cheminformatics solutions, today announced that it has entered into an agreement with Pfizer Inc., to provide Orion, OpenEye’s new cloud platform, to the company’s Medicinal Sciences division.  Orion will equip chemists with all of OpenEye’s software, extensive tools for data visualization and communication, useful data sources and customizable, task-oriented workflows, all in a robust, scalable, cloud environment.

“We believe that Orion has the potential to revolutionize how computation is delivered to the pharmaceutical industry,” said Dr. Anthony Nicholls, CEO and founder of OpenEye Scientific Software, Inc. “Orion marries the immense resource of cloud computing services, with our insights, science and tools from two decades of helping customers. It continues and expands our tradition of computing at scale, reliable, predictive science and facilitating local innovation. As an open, collaborative platform for both industry and academia we think it can enhance the drug discovery process.”

“We look forward to implementing Orion’s workflow tools to help our efforts to deliver potential breakthrough therapies for patients,” said Enoch Huang, Executive Director of Computational Sciences at Pfizer.

About OpenEye

OpenEye has built a reputation as a scientific leader in the field of molecular design based on two decades of delivering useful applications and programming toolkits. Our scientific approach has focused on the power of molecular 3D structure to inform and guide, in particular via the concept of shape similarity. We have changed industry perception of what is possible with the speed, robustness and scalability of our tools and have recently built these into a ground-up, cloud-native platform, Orion. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization. OpenEye Scientific is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts, Cologne, Germany, Strasbourg, France and Tokyo, Japan.  For further information on the company and its products, see www.eyesopen.com.

FOR ADDITIONAL INFORMATION

OPENEYE SCIENTIFIC SOFTWARE, INC.

Jeffrey Grandy, Vice President, Sales

+1 505-473-7385 x60

Email: sales@eyesopen.com